Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
2 "Rupert W Leong"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Review
IBD
Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition
Filiz Akyüz, Yoon Kyo An, Jakob Begun, Satimai Aniwan, Huu Hoang Bui, Webber Chan, Chang Hwan Choi, Nazeer Chopdat, Susan J Connor, Devendra Desai, Emma Flanagan, Taku Kobayashi, Allen Yu-Hung Lai, Rupert W Leong, Alex Hwong-Ruey Leow, Wai Keung Leung, Julajak Limsrivilai, Virly Nanda Muzellina, Kiran Peddi, Zhihua Ran, Shu Chen Wei, Jose Sollano, Michelle Mui Hian Teo, Kaichun Wu, Byong Duk Ye, Choon Jin Ooi
Intest Res 2025;23(1):37-55.   Published online November 4, 2024
DOI: https://doi.org/10.5217/ir.2024.00089
AbstractAbstract PDFPubReaderePub
The lack of clear definition and classification for “moderate ulcerative colitis (UC)” creates ambiguity regarding the suitability of step-up versus top-down treatment approaches. In this paper, experts address crucial gaps in assessing and managing moderate UC. The Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition comprised 24 experts who convened to share, discuss and vote electronically on management recommendations for moderate UC. Experts emphasized that the goal of treating UC is to attain clinical, biomarker, and endoscopic remission using cost-effective strategies such as 5-aminosalicylates (5-ASAs), well-tolerated therapy that can be optimized to improve outcomes. Experts agreed that 5-ASA therapy could be optimized by maximizing dosage (4 g/day for induction of remission), combining oral and topical administration, extending treatment duration beyond 8 weeks, and enhancing patient adherence through personalized counselling and reduced pill burden. Treatment escalation should ideally be reserved for patients with predictors of aggressive disease or those who do not respond to 5-ASA optimization. Premature treatment escalation to advanced therapies (including biologics and oral small molecules) may have long-term health and financial consequences. This paper provides consensus-based expert recommendations and a treatment algorithm, based on current evidence and practices, to assist decision-making in real-world settings.

Citations

Citations to this article as recorded by  
  • Inflammatory bowel disease in Africa: the current landscape of pharmacological treatments and the promise of emerging innovations
    Murtada A. Oshi
    Exploration of Drug Science.2025;[Epub]     CrossRef
  • 19,569 View
  • 379 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Original Article
IBD
The association between new generation oral contraceptive pill and the development of inflammatory bowel diseases
Santosh Sanagapalli, Yanna Ko, Viraj Kariyawasam, Siew C Ng, Whitney Tang, Hithanadura Janaka de Silva, Minhu Chen, Kaichun Wu, Satimai Aniwan, Ka Kei Ng, David Ong, Qin Ouyang, Ida Hilmi, Marcellus Simadibrata, Pises Pisespongsa, Saranya Gopikrishna, Rupert W Leong
Intest Res 2018;16(3):409-415.   Published online July 27, 2018
DOI: https://doi.org/10.5217/ir.2018.16.3.409
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

To examine the association between use of oral contraceptive pills (OCPs) and the risk of developing inflammatory bowel diseases (IBD), in a modern cohort.

Methods

A prospective nested case-control study across sites in the Asia-Pacific region was conducted; involving female IBD cases and asymptomatic controls. Subjects completed a questionnaire addressing questions related to OCP use. Primary outcome was the risk of development of IBD of those exposed to OCP versus non-exposure. Secondary outcomes were development of Crohn's disease (CD) versus ulcerative colitis (UC), and whether age of first use of OCP use may be associated with risk of IBD.

Results

Three hundred and forty-eight female IBD cases (41% CD, median age: 43 years) and 590 female age-matched controls were recruited. No significant association was found between OCP use and the risk of IBD (odds ratio [OR], 1.65; 95% confidence interval, 0.77–3.13; P=0.22), CD (OR, 1.55) or UC (OR, 1.01). The lack of association persisted when results were adjusted for age and smoking. IBD cases commenced OCP use at a younger age than controls (18 years vs. 20 years, P=0.049).

Conclusions

In this large cohort of subjects from the Asia-Pacific region, we found a modest but not significantly increased risk of developing IBD amongst OCP users.

Citations

Citations to this article as recorded by  
  • Sex-related differences in profiles and clinical outcomes of Inflammatory bowel disease: a systematic review and meta-analysis
    Dana A. Salem, Rawan El-Ijla, Razan R. AbuMusameh, Khaled A. Zakout, Alaa Y. Abu Halima, Mohammed T. Abudiab, Yahya M. Banat, Basel F. Alqeeq, Mohammed Al-Tawil, Khaled Matar
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Estrogen receptor actions in colitis
    Erika L. Garcia-Villatoro, Clinton D. Allred
    Essays in Biochemistry.2021; 65(6): 1003.     CrossRef
  • Sex-based differences in inflammatory bowel diseases: a review
    Sheila D. Rustgi, Maia Kayal, Shailja C. Shah
    Therapeutic Advances in Gastroenterology.2020;[Epub]     CrossRef
  • 11,590 View
  • 109 Download
  • 4 Web of Science
  • 3 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP